Background. Immunization of pregnant women with tetanus-diphtheria-acellular pertussis vaccine (Tdap) provides protection against pertussis to the newborn infant.
Pertussis is an acute respiratory tract infection that is most severe in young infants and can lead to hospitalization, intensive care unit admission, and death [1] [2] [3] [4] [5] [6] . Despite widespread childhood vaccination, there has been a recent resurgence of pertussis in a number of countries and an increase in reported deaths [7] [8] [9] [10] . Although the first dose of pertussis vaccine may provide some protection against fatal infection [11] , full protection is not achieved until completion of the primary series. This leaves a period of susceptibility for at least the first 2-3 months of life.
Immunization during pregnancy to provide protection to the newborn via transplacental transfer of antibodies has been proposed for >80 years [12] [13] [14] and is recommended in some countries [15] [16] [17] . Although maternal antibody protects the newborn infant, high levels of transplacentally acquired antibody might blunt the immune response to active immunization. We examined the safety and immunogenicity of an adult formulation of tetanus-diphtheria-acellular pertussis vaccine (Tdap) or tetanus-diphtheria vaccine (Td) given in the third trimester of pregnancy and studied the effect of passive antibody on the postimmunization antibody response in the newborn.
assessed at ≥30 weeks' gestation to be at low risk for complications were eligible for enrollment. Exclusion criteria were high obstetrical risk, history of significant medical disorder, receipt of high-dose systemic corticosteroids, history of physician-diagnosed pertussis in the last 5 years, receipt of Td or Tdap in the last 5 years, sensitivity to any component of Td or Tdap, receipt of blood products or immunoglobulin within 3 months of study entry (except rhesus immunoglobulin during pregnancy), or receipt of any vaccines within 2 weeks of study vaccine (except for influenza vaccine, which could be given concurrently). The first 50 participants were enrolled in Halifax from November 2007 to June 2011, after which there was a preplanned safety pause for a blinded interim safety and immunogenicity analysis by the data monitoring and safety board. The remaining participants were then enrolled in Halifax, Montreal, Ottawa, Calgary, Edmonton, and Vancouver from March 2012 to April 2014. The protocol was approved by the research ethics boards of all sites (ClinicalTrials.gov identifier NCT00553228).
Study Procedures
After written informed consent was obtained, an obstetrical algorithm and checklist (see Supplementary Appendix) were used to confirm eligibility. Participants were randomly allocated using a computer-generated randomization list in a 1:1 ratio in balanced blocks of 4 to receive Td or Tdap. Td was selected as the comparator (rather than placebo) to better focus the analysis on the effect of the pertussis antigens. Only the unblinded nurse at each site had access to the randomization list and prepared and administered the assigned vaccine; the unblinded nurse did not have any further involvement in the study. For the infants, routine concomitant immunizations were given according to each child's provincial recommendations [18] .
Participants were contacted 8 days postimmunization to collect solicited and unsolicited adverse events (AEs). Visits to collect maternal and infant sera took place at the time of the infant's scheduled immunization visits at 2, 4, 6, and 12 months of age (the booster dose was given early at 12 months of age, rather than the routinely scheduled 18 months of age, to address the possibility of interference of maternal immunization with the infant's response to vaccination). Serum was also collected 1 month after completion of the primary series (at 7 months of age) and 1 month after the booster dose (at 13 months of age; maternal blood was not collected at the 13-month visit). A final visit took place at >18 months of age for developmental testing using the Bayley-III Scales of Infant and Toddler Development.
Vaccines
Licensed vaccines were used for the immunization of women and infants (Table 1 ) and were administered into the deltoid muscle in adults and children >1 year of age or into the anterolateral aspect of the thigh in infants. Concomitant vaccines (pneumococcal conjugate vaccine, meningococcal C conjugate vaccine, measles-mumps-rubella-varicella vaccine) were obtained from provincial sources and given according to provincial schedules.
Clinical and Laboratory Monitoring
Solicited injection-site (erythema, swelling, pain) and systemic (fever, headache, muscle ache, fatigue) AEs were recorded on a diary card for 7 days postimmunization for the pregnant women. Adverse events were either measured (injection-site erythema and swelling, and fever) or graded for severity (none; 
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Primary and Secondary Outcomes
The primary immunogenicity outcome was whether the antibody levels of newborns of Tdap-immunized mothers at birth were noninferior to the antibody levels of infants of Td-immunized women after the second primary infant dose (at 6 months of age). The secondary outcome was the comparison between groups of seroprotection rates (>0.1 IU/mL for tetanus and diphtheria antibodies) and geometric mean antibody concentrations (GMCs) and their 2-sided 95% confidence intervals (CIs) at each time point. Blunting of the antibody response (defined as a statistically significant difference) was evaluated by comparing GMCs at 7 months of age (post-primary series) and 13 months of age (post-booster dose) in infants of mothers who received Tdap to those who received Td.
Data Management and Statistical Testing
Descriptive analyses were performed using SAS statistical software version 9.3 or later (SAS Institute, Cary, North Carolina). Medical history and AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 19.0. Categorical variables were summarized by number and percentage of subjects within each category. For continuous variables, geometric means and 95% CIs were calculated. The serological assay lower limit of quantitation was 4 EU/mL for PT, PRN, and FIM, 3 EU/mL for FHA, 0.06 µL/mL for PRP, 0.005 IU/mL for diphtheria, and 0.01 IU/mL for tetanus; samples reported with a concentration lower than these threshold levels were entered as one-half the level. Statistical hypothesis testing was conducted at a 2-sided .05 significance level.
Sample Size Calculations
The sample size calculation was based on the primary immunogenicity outcome. Noninferiority was defined as the GMC of infants of Td-vaccinated women exceeding that of infants of Tdapimmunized women by no more than 1.35 EU/mL, based on variance of antibody levels post-dose 2 determined in previous clinical trials. A sample size of 194 per group was determined to provide a power of 0.8 when tested at level .05. A sample size of 110 per group provided a power of 0.8 at level .05 when noninferiority was defined as a difference in log antibody concentrations no more than 0.4.
RESULTS
Demographics
A total of 304 women were enrolled; 273 women were randomized and immunized with Td (n = 138) or Tdap (n = 135) ( Figure 1 ). There were no baseline demographic differences between the women randomized to the Td or Tdap groups (Table 2 ). Of the 272 infants born, 126 of 138 (91.3%) infants of Td-recipient mothers and 121 of 134 (90.3%) infants of Tdaprecipient mothers completed the study.
Safety Outcomes
Injection-site pain was reported by >80% of both Td and Tdap recipients; most pain was described as mild or moderate and was similar in both groups ( Figure 2A ). Muscle aches, fatigue, and headache were reported by 16.9%-34.4% of participants ( Figure 2B ). Mild fatigue was more common in Td than in Tdap recipients (23.4% vs 13.3%; P = .041). Mild muscle aches were more common in Td recipients (20.4% vs 4.4%; P < .001), whereas severe muscle aches were more common in Tdap recipients (4.4% vs 0%; P = .014). Eight SAEs were reported in Td recipients and 6 SAEs in Tdap recipients; none were assessed by the blinded local investigator to be vaccine related (Table 3 ). There were no differences in rates of congenital abnormalities or neonatal complications. There were 17 serious complications of pregnancy/labor (9 in Td recipients, and 8 in Tdap recipients); 4 of these events were assessed as possibly vaccine-related (preeclampsia, premature delivery, and HELLP syndrome [hemolysis, elevated liver enzymes, low platelet count] in 1 Td recipient and gestational hypertension in 1 Tdap recipient). There were 29 SAEs in infants of Td-recipient mothers and 20 SAEs in infants of Tdap-recipient mothers; none were assessed by the local investigator to be vaccine-related. No cases of pertussis were observed. No developmental differences were detected with the Bayley assessment at 18 months of age (Table 2) .
Immunogenicity
Women
Both Td and Tdap elicited vigorous antibody responses ( Figure 3) . In Tdap recipients, antibodies against PT, FHA, PRN, and FIM reached peak levels by delivery or by 2 months postpartum and were significantly higher than those of Td recipients at all postimmunization time points. With diphtheria and tetanus, there were no differences in the proportion of participants achieving levels ≥0.1 IU/ mL postimmunization. In the Tdap group, antibody levels against all pertussis antigens decreased by just over 50%; however, these levels remained significantly higher than preimmunization levels. Figure 2. Proportion of women reporting an injection-site reaction (A) and a systemic adverse event (B) after immunization with tetanus-diphtheria-acellular pertussis vaccine, adult formulation, (Tdap; n = 133-135) or tetanus-diphtheria vaccine (Td; n = 134-137). Black = mild; white = moderate; cross-hatch = severe. *P < .05 (mild fatigue, severe muscle aches); **P < .001 (mild muscle aches). 
Infants
At birth, significantly higher antibody levels against PT, FHA, PRN, and FIM were found in infants of women who had been immunized with Tdap compared with those immunized with Td (Table 4 ). There were no differences in cord blood antibody levels against diphtheria or tetanus in infants of Td-or Tdapimmunized women. Fetal to maternal antibody ratios were >1 for PT, FHA, FIM, diphtheria, and tetanus in Tdap-recipient fetal-maternal pairs and for all antigens in Td-recipient pairs, suggesting active transport of antibody across the placenta (Table 5 ). The primary outcome measure was met for all 4 pertussis antibodies; antibody levels at birth in the infants of Tdap-immunized women were noninferior to the antibody levels at 6 months (post-infant primary series dose 2) in infants of Td-immunized women. Although pertussis antibody levels at birth and at 2 months of age were significantly higher in infants of Tdap-immunized women compared with infants of Td-immunized women (Figure 4 ), these higher levels diminished over time. At 4 months of age, antibody levels were significantly higher in infants of Tdap-immunized women for FHA, PRN, and FIM and not significantly different for PT. By 6 months of age, antibody levels against PT and FHA were significantly lower in infants of Tdap-immunized women compared with infants of Td-immunized women; PRN and FIM were similar in the 2 groups. By 7 months of age, antibody levels against all pertussis antigens were significantly lower in infants of Tdap-immunized women. These significantly lower levels persisted for all pertussis antibodies at 12 months of age and for PT, FHA, and FIM postbooster. For most time points, there were no significant differences in antibody response to diphtheria, tetanus, or PRP between infants of Tdap-or Td-immunized women. Infants of Tdap-immunized women had marginally but significantly higher diphtheria antibody levels at 6 months of age and tetanus antibody levels at 12 months.
DISCUSSION
In this trial, Tdap elicited a vigorous antibody response in women when administered during the third trimester of pregnancy, and provided high levels of antibodies to the fetus. The primary immunological outcome that infants of Tdapimmunized women would have antibody levels at birth noninferior to the levels in control infants of Td-immunized women at 6 months of age (post-primary series dose 2) was achieved; indeed, levels provided at birth were equivalent (PT) or superior (FHA, PRN, FIM) to those achieved post-primary series dose 3 and postbooster at 13 months of age. However, these high antibody levels achieved at birth were not without cost; although infants of Tdap-immunized women had significantly higher PT antibody levels at birth and 2 months of age and significantly higher FHA, PRN, and FIM antibodies at birth and 2 and 4 months of age than infants of Td-immunized women, they had significantly lower PT and FHA antibody levels at 6 and 7 months of age and significantly lower PRN and FIM antibody levels at 7 months of age. These differences persisted Abbreviations: GERD, gastroesophageal reflux disease; HELLP, hemolysis, elevated liver enzymes, low platelet count; RSV, respiratory syncytial virus; Td, tetanus-diphtheria vaccine; Tdap, tetanus-diphtheria-acellular pertussis vaccine, adult formulation. a All SAEs were considered by the investigator to be not related to vaccination except for prebooster at 12 months for all pertussis antibodies and postbooster for PT, FHA, and FIM. Our study provides further support regarding the tolerability of Tdap when given during pregnancy. Similar to studies comparing Tdap to Td in nonpregnant adolescents and adults [19] , we did not see any clinically or statistically significant differences in injection-site events reported by recipients of either Td or Tdap, nor did we see any differences in SAEs. Large observational studies have not identified any SAEs or adverse pregnancy outcomes associated with Tdap during pregnancy [20] [21] [22] [23] .
Both Td and Tdap were immunogenic when given to pregnant women and steadily declined by 12 months postpartum. These results are similar to those of previous studies of immunogenicity in young adults [19, 24] and pregnant women [25] [26] [27] [28] and antibody persistence in young adults [29, 30] and pregnant women [31] .
This study provides new data concerning the blunting of the immune response to active, primary series immunization in infants of women immunized with Tdap during pregnancy. In a small RCT, Munoz et al [25] reported significantly lower antibody concentrations to FHA but no differences to PT, PRN, and FIM at 7 months of age in infants of women immunized with the same Tdap vaccine used in this study; there were no significant differences after the booster dose. However, antibody concentrations to all of the pertussis antigens in the Tdap and control group were similar to those in our study; the failure to demonstrate a difference in that study was likely the result of the small sample size. Ladhani et al [27] reported a lower antibody response compared with historical controls in the United Kingdom after implementation of their universal Tdap-inactivated poliovirus vaccine immunization program during pregnancy. In a nonrandomized, prospective study of women either immunized (n = 57) or not immunized (n = 42) with Tdap during pregnancy, Maertens et al [28] found significantly lower levels of PT and nonsignificantly lower levels of PRN post-primary series and booster [32] ; small sample size (only 21 infants of control women provided sera) may have contributed to the lack of statistical significance. In another RCT in Vietnam (n = 35 infant sera post-primary series), PRN antibody levels, but not PT or FHA, were lower in infants of women immunized with Tdap during pregnancy [26] ; PRN concentrations were nonsignificantly lower after the booster dose, perhaps a result of the small sample size (n = 30 in the Tdap group) [33] . In our study, with a total of 239 infant sera assayed at the booster dose (3.6-to 6-fold the number in prior studies), the differences in antibody levels between the groups were statistically significant after the primary series and persisted after a booster dose.
The clinical significance of the blunted immune response to pertussis antigens in infants of mothers immunized with Tdap is unclear. There is accumulating evidence from England and Wales [34, 35] and the United States [36] that maternal immunization with Tdap is effective in preventing pertussis in newborn infants. Because virtually all deaths from pertussis occur in infants <3 months of age [1] [2] [3] [4] [5] [6] , particularly in those who have not had a first dose of pertussis vaccine [11] , maternal immunization is achieving its goal of preventing pertussis deaths in the first months of life. If antibody levels after the primary series are lower in infants of women immunized with Tdap, this could lead to an increased burden of pertussis disease in the second half of the first year of life or afterward. Early surveillance data from England and Wales [37] has not identified any increase in cases later in infancy, but longer follow-up is required. Although there is a potential for increased number of pertussis cases in later infancy, these are not usually associated with mortality; therefore, this outcome may be acceptable if pertussis deaths in early infancy are prevented. This large RCT provides the strongest evidence to date of the effectiveness of maternal immunization in providing high levels of transplacental antibodies against pertussis to newborn infants and the persistence of those high levels to 2-4 months of age. It demonstrated that these high levels of antibodies led to a blunting of the immune response to the primary pertussis vaccine series that persisted beyond the booster dose in the second year of life. The study is not without limitations; although the enrollment target was not achieved, the primary and secondary outcomes were met. Although large, the study was not powered to detect rare AEs following immunization or adverse pregnancy outcomes. The multiple study sites were all in Canada and most participants were white; thus, the results might not be generalizable to all populations. Receipt of Tdap in the prior 5 years was an exclusion to participation, limiting the ability to address repeat Tdap with each subsequent pregnancy. In addition, all infants in our study were immunized with acellular pertussis vaccine and the effects of maternal immunization with Tdap on an infant series with whole-cell pertussis-containing vaccines, which are used in many parts of the world, may differ. In addition, as all of the women received tetanus and diphtheria vaccine, we were unable to assess the effect of Td vaccine during pregnancy on the infants' response to diphtheria and tetanus immunization or to vaccines using a tetanus or diphtheria toxoid-based conjugate. Finally, it is not known at what age in early childhood the antibody blunting effect disappears. Ongoing surveillance of pertussis in early childhood is needed when maternal immunization programs are implemented. 
